Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

7.3%

4 terminated out of 55 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

7%

4 trials in Phase 3/4

Results Transparency

28%

5 of 18 completed with results

Key Signals

5 with results82% success

Data Visualizations

Phase Distribution

42Total
Not Applicable (18)
Early P 1 (1)
P 1 (11)
P 2 (8)
P 3 (3)
P 4 (1)

Trial Status

Completed18
Recruiting13
Unknown9
Active Not Recruiting5
Terminated4
Not Yet Recruiting3

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (55)

Showing 20 of 20 trials
NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT07114601Phase 1Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07699705Not ApplicableRecruitingPrimary

Prospective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer

NCT06915909Not ApplicableRecruiting

Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial

NCT05422105Suspended

Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

NCT05710380Not ApplicableRecruiting

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

NCT06315595RecruitingPrimary

Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI

NCT03424850Phase 1Recruiting

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

NCT04075305Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT04019327Phase 1Completed

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

NCT07238959Not Yet Recruiting

Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer

NCT05252390Phase 1Terminated

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

NCT05276492Phase 1Terminated

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

NCT03493945Phase 1Completed

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

NCT03344757Not ApplicableCompletedPrimary

Health Gatherings - For Your Health After Cancer

NCT04030338Active Not Recruiting

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

NCT05137561Phase 2Completed

Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)

NCT04053842Phase 2Active Not Recruiting

Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy

NCT03822494Not ApplicableActive Not Recruiting

CyberKnife Dose Escalation Prostate Cancer Trial

NCT06784986Phase 4Recruiting

Impact of Using the Airseal System with Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: a Prospective, Comparative, Randomized Clinical Study.

Scroll to load more

Research Network

Activity Timeline